<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> is beside <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> frequently accompanied by <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e>, arterial <z:hpo ids='HP_0000822'>hypertension</z:hpo>, <z:hpo ids='HP_0001513'>obesity</z:hpo> and other <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> risks </plain></SENT>
<SENT sid="1" pm="."><plain>The article summarizes current status demonstrating that we are far from recommended targets, especially with <z:mp ids='MP_0002055'>diabetes</z:mp>, blood pressure and <z:chebi fb="23" ids="18059">lipid</z:chebi> controls </plain></SENT>
<SENT sid="2" pm="."><plain>More aggressive drug treatment together with life style changes will be necessary to reach our goals in Type 2 diabetic patients </plain></SENT>
</text></document>